Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease

NCT00766363 is registered in ClinicalTrials.gov with FORUM Pharmaceuticals Inc as lead sponsor.

NCT NCT00766363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00766363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease
Lead sponsor
FORUM Pharmaceuticals Inc
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
March 31, 2009
Enrollment
49 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, central nervous system diseases